Tioma raises $86M for anti-CD47 antibodies

Immuno-oncology play Tioma Therapeutics Inc. (Brisbane, Calif.) raised $86 million in a series A round co-led by RiverVest Venture Partners, Novo Ventures, Roche Venture Fund and SR One.

Tioma also named John Donovan president and CEO. He was co-founder, CBO and CFO of antiviral company Alios BioPharma Inc., which Johnson & Johnson (NYSE:JNJ) acquired. ...